Acadia Healthcare Exceeds Q1 Adjusted EBITDA Guidance, Raises Full-Year Outlook

summarizeSummary

Acadia Healthcare reported strong first-quarter results, surpassing its Adjusted EBITDA guidance, and subsequently raised its full-year Adjusted EBITDA, Adjusted EPS, and Operating Cash Flow guidance.

check_boxKey Events

• Strong Q1 Performance

  Acadia Healthcare reported first-quarter revenue of $828.8 million, a 7.6% increase year-over-year, and Adjusted EBITDA of $144.2 million, a 7.5% increase, exceeding the high end of its guidance.

• Raised Full-Year Guidance

  The company increased its full-year 2026 Adjusted EBITDA guidance to a range of $580-$615 million (from $575-$610 million) and Adjusted EPS guidance to $1.35-$1.60 (from $1.30-$1.55).

• Increased Operating Cash Flow Outlook

  Full-year operating cash flow guidance was also raised to $285-$325 million (from $280-$320 million).

• Capacity Expansion

  Acadia added 82 newly licensed beds during the first quarter, including 42 beds to existing facilities and 40 beds from newly constructed facilities.

auto_awesomeAnalysis

Acadia Healthcare's first-quarter performance demonstrated solid operational execution, with revenue increasing by 7.6% and Adjusted EBITDA growing by 7.5% year-over-year, exceeding the high end of its own guidance. The company's decision to raise its full-year Adjusted EBITDA, Adjusted EPS, and Operating Cash Flow guidance signals management's confidence in continued strong performance. This positive outlook, driven by strong patient volumes and operating efficiencies, provides a favorable signal to investors regarding the company's financial health and growth trajectory.